Lonza is a leading supplier to the pharmaceutical, biotech and specialty ingredients markets.
The layoffs are a result of a companywide realignment as the it builds four cell and gene therapy centers in the U.S., the Netherlands and Singapore, a company spokesperson told BioPharma Dive.
The Maryland plant will shift its focus from cell therapy production to bioscience solutions.
The layoffs are expected to occur over a one-year period.
More articles on pharmacy:
Drug take back day is Oct. 27: 5 things to know
Amgen cuts list price of $14K-a-year cholesterol drug nearly 60%
Trump’s plan to lower prescription drug prices: 7 takeaways
